Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide

被引:213
作者
Muench, Jan
Staendker, Ludger
Adermann, Knut
Schuz, Axel
Schindler, Michael
Chinnadurai, Raghavan
Poehlmann, Stefan
Chaipan, Chawaree
Biet, Thorsten
Peters, Thomas
Meyer, Bernd
Wilhelm, Dennis
Lu, Hong
Jing, Weiguo
Jiang, Shibo
Forssmann, Wolf-Georg [1 ]
Kirchhoff, Frank
机构
[1] IPF PharmaCeut GmbH, D-30625 Hannover, Germany
[2] Univ Ulm, Inst Virol, D-89081 Ulm, Germany
[3] VIRO Pharmaceut GmbH & Co KG, D-30625 Hannover, Germany
[4] Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany
[5] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr, D-91054 Erlangen, Germany
[6] Med Univ Lubeck, Inst Chem, D-23538 Lubeck, Germany
[7] Univ Hamburg, Fac Sci, D-20146 Hamburg, Germany
[8] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA
[9] Hannover Med Sch, Ctr Pharmacol, D-30625 Hannover, Germany
基金
美国国家卫生研究院;
关键词
D O I
10.1016/j.cell.2007.02.042
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A variety of molecules in human blood have been implicated in the inhibition of HIV-1. However, it remained elusive which circulating natural compounds are most effective in controlling viral replication in vivo. To identify natural HIV-1 inhibitors we screened a comprehensive peptide library generated from human hemofiltrate. The most potent fraction contained a 20-residue peptide, designated VIRUS-INHIBITORY PEPTIDE (VIRIP), corresponding to the C-proximal region of alpha 1 -antitrypsin, the most abundant circulating serine protease inhibitor. We found that VIRIP inhibits a wide variety of HIV-1 strains including those resistant to current antiretroviral drugs. Further analysis demonstrated that VIRIP blocks HIV-1 entry by interacting with the gp41 fusion peptide and showed that a few amino acid changes increase its antiretroviral potency by two orders of magnitude. Thus, as a highly specific natural inhibitor of the HIV-1 gp41 fusion peptide, VIRIP may lead to the development of another class of antiretroviral drugs.
引用
收藏
页码:263 / 275
页数:13
相关论文
共 47 条
[1]  
ANDERSON ED, 1993, J BIOL CHEM, V268, P24887
[2]   HIV-1 resistance to the gp41-dependent fusion inhibitor C-34 [J].
Armand-Ugón, M ;
Gutiérrez, A ;
Clotet, B ;
Esté, JA .
ANTIVIRAL RESEARCH, 2003, 59 (02) :137-142
[3]   CLINICAL-FEATURES AND HISTORY OF THE DESTRUCTIVE LUNG-DISEASE ASSOCIATED WITH ALPHA-1-ANTITRYPSIN DEFICIENCY OF ADULTS WITH PULMONARY SYMPTOMS [J].
BRANTLY, ML ;
PAUL, LD ;
MILLER, BH ;
FALK, RT ;
WU, M ;
CRYSTAL, RG .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 138 (02) :327-336
[4]   Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target [J].
Chan, DC ;
Chutkowski, CT ;
Kim, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) :15613-15617
[5]   HIV-1 REVERSE TRANSCRIPTION - A TERMINATION STEP AT THE CENTER OF THE GENOME [J].
CHARNEAU, P ;
MIRAMBEAU, G ;
ROUX, P ;
PAULOUS, S ;
BUC, H ;
CLAVEL, F .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 241 (05) :651-662
[6]   PROTEOLYTIC INACTIVATION OF ALPHA-1-PROTEINASE INHIBITOR BY A NEUTROPHIL METALLOPROTEINASE [J].
DESROCHERS, PE ;
WEISS, SJ .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (05) :1646-1650
[7]   Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties [J].
Detheux, M ;
Ständker, L ;
Vakili, J ;
Münch, J ;
Forssmann, U ;
Adermann, K ;
Pöhlmann, S ;
Vassart, G ;
Kirchhoff, F ;
Parmentier, M ;
Forssmann, WG .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (10) :1501-1508
[8]   HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells [J].
Eckstein, DA ;
Sherman, MP ;
Penn, ML ;
Chin, PS ;
De Noronha, CMC ;
Greene, WC ;
Goldsmith, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (10) :1407-1419
[9]   Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV [J].
Eron, JJ ;
Gulick, RM ;
Bartlett, JA ;
Merigan, T ;
Arduino, R ;
Kilby, JM ;
Yangco, B ;
Diers, A ;
Drobnes, C ;
DeMasi, R ;
Greenberg, M ;
Melby, T ;
Raskino, C ;
Rusnak, P ;
Zhang, Y ;
Spence, R ;
Miralles, GD .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (06) :1075-1083
[10]   SOLID-PHASE PEPTIDE-SYNTHESIS UTILIZING 9-FLUORENYLMETHOXYCARBONYL AMINO-ACIDS [J].
FIELDS, GB ;
NOBLE, RL .
INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, 1990, 35 (03) :161-214